Malcisbo, Zurich, Switzerland

Malcisbo develops novel carbohydrate-based vaccines for human and animal health. Our focus is on parasitic diseases, on human food safety and on zoonotic diseases.

The company has developed its proprietary target discovery platform to identify carbohydrates as vaccine targets. Employing our glycoengineering technologies, we develop novel and efficient glycoconjugate vaccines. Malcisbo is developing a strong pipeline of novel vaccine products coming out of this platform for unmet needs in human and veterinary medicine.

Our first vaccines target the medical areas of ruminant Haemonchus contortus, porcine Actinobacillus pleuropneumoniae infections (prevention of economic loss during food production) and chicken Campylobacter infections (prevention of human food poisoning).

The vaccine to the red stomach worm Haemonchus contortus serves as a proof of concept for a technology which then may be used to fight other parasites in humans (e.g. hookworm) and animals (e.g. heartworm).

We employ a strong multi-disciplinary team of 6 people exhibiting complementary skills in different areas. The company maintains an extensive international network. Malcisbo, domiciled in Schlieren, Switzerland, was incorporated in May 2010 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH Zurich).

Please visit our homepage